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One- and two-stage surgical revision of
infected elbow prostheses following total
joint replacement: a systematic review
Setor K. Kunutsor1,2* , Andrew D. Beswick2, Michael R. Whitehouse1,2 and Ashley W. Blom1,2
Abstract
Background: Prosthetic joint infection (PJI) is a challenging complication of total elbow replacement (TER).
Potential surgical treatments include one- or two-stage revision; however, the best treatment for elbow PJI is not
clearly defined. We conducted a systematic review in accordance with PRISMA guidelines to compare the clinical
effectiveness of one- and two-stage revision surgery for elbow PJI using re-infection (recurrent and new infections)
rates; mortality; clinical measures of function, pain, and satisfaction; and non-infection related adverse events.
Methods: MEDLINE, Embase, Web of Science, and The Cochrane Library were searched up to June 2019 to identify
observational cohort studies and randomised controlled trials (RCTs) that had recruited patients with elbow PJI
following TER and treated with one- or two-stage revision. Of 96 retrieved articles, 2 one-stage and 6 two-stage
revision studies were eligible. No RCT was identified. Arcsine transformation was used in estimating rates with 95%
confidence intervals (CIs).
Results: Staphylococcus aureus was the most common causative organism for PJI of the elbow (24 of 71 elbow PJIs).
The re-infection rate (95% CI) for one-stage (7 elbows) ranged from 0.0% (0.0–79.3) to 16.7% (3.0–56.4) and that for
two-stage revision (87 elbows) from 0.0% (0.0–49.0) to 20.0% (3.6–62.4). Non-infection related adverse event rate for
one-stage (based on a single study) was 16.7% (3.0–56.4) and that for two-stage ranged from 11.8% (4.7–26.6) to 20.0%
(3.6–62.4). There were no mortality events recorded following one- or two-stage revision surgery and postoperative
clinical measures of function, pain, and satisfaction could not be effectively compared because of limited data.
Conclusions: No strong conclusions can be drawn because of limited data. The one-stage revision may be potentially
at least as clinically effective as two-stage revision, but further data is needed. There are clear gaps in the existing
literature and studies are urgently warranted to assess the clinical effectiveness of one- and two-stage revision
strategies for PJI following TER.
Systematic review registration: PROSPERO 2018: CRD42018118002.
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Background
Common complications following total elbow replace-
ment (TER) include implant loosening, periprosthetic
fracture, implant failure, triceps insufficiency, nerve palsy,
and prosthetic joint infection (PJI) [1]. Compared to lower
extremity joint replacements, relatively few elbow replace-
ments are performed. In 2017, as recorded in the National
Joint Registry for England, Wales and Northern Ireland
and the Isle of Man, approximately 100,000 joint replace-
ments were performed each in knees and hips; whereas
only 612 elbow replacements were performed [2]. How-
ever, it has been reported that the proportion of complica-
tions associated with elbow replacements is greater than
that for hip or knee replacements [3].
Prosthetic joint infection (PJI) is a potentially devastat-
ing complication of TER and compared with hip or knee
replacement, TER is associated with a higher incidence
of PJI which affects between 1 to 12% of patients [4–6].
PJI after TER is associated with significant morbidity [7]
as well as increased costs to the healthcare system [8].
Treatment of elbow PJI is a challenging task [9] and the
key goals are clearing infection, retaining maximum joint
function, and pain relief. Treatment options for elbow
PJI include debridement, treatment with antibiotics and
retention of the prosthesis (DAIR); resection arthro-
plasty; and one- or two-stage revision [10]. Resection
arthroplasty is generally considered a salvage procedure
and used as a last resort in refractory PJI after TER or in
patients for whom loss of elbow function is of less con-
cern [11, 12]. The best treatment for elbow PJI is not
clearly defined as choices of treatment strategy are gen-
erally based on the treating surgeon’s experience and
evidence derived from studies of PJI treatment in hip
and knee replacement [13]. Based on existing data, the
two-stage revision strategy appears to be the most com-
monly used treatment option for elbow PJI [10]. The
one-stage revision strategy may be a putative alternative
treatment. An extensive body of evidence suggests that
one- and two-stage revision strategies for hip, knee and
shoulder PJI are clinically comparable [14–17]; however,
the data are sparse and conflicting on the role of these
strategies for treating infected elbow prostheses. To our
knowledge, no study has yet reviewed the existing evi-
dence by comparing results of published studies that
have reported clinical outcomes on any of these two re-
vision strategies. We are also not aware of any rando-
mised controlled trial (RCT) that has compared the
clinical effectiveness of the two revision strategies.
To clarify the existing evidence, we conducted a sys-
tematic review to compare the clinical effectiveness of
the one- and two-stages revision strategies for elbow PJI
using infection control as the primary outcome. Second-
ary objectives included (i) comparing the effectiveness of
the two revision strategies based on other clinical
outcomes which include mortality; validated measures of
function, pain, and satisfaction; as well as non-infection
related adverse events and (ii) to explore any gaps in the
evidence base.
Methods
Data sources and search strategy
We registered this review in the PROSPERO prospective
register of systematic reviews (CRD42018118002). The
review was based on a protocol which was predefined
and performed following PRISMA and MOOSE guide-
lines [18, 19]. We systematically searched MEDLINE,
Embase, and The Cochrane library from inception to 25
June 2019 for longitudinal observational studies and
RCTs that reported on infection control and/or other
clinical endpoints after one- or two-stage surgical revision
of an infected elbow prostheses. The computer-based
searches employed a combination of free and MeSH
search terms and key words related to the intervention,
population and outcomes. Only human studies were
searched for, with no restrictions placed on language. The
full search strategy is reported in Additional file 1: Table
S1. The retrieved citations were initially screened based
on their titles and abstracts to assess their potential for in-
clusion, after which we retrieved potentially eligible arti-
cles for full text evaluation. Evaluation of full texts was
conducted by two independent authors (S.K.K., A.D.B.)
based on the inclusion criteria and any disagreements re-
garding whether an article should be included or not was
discussed, with involvement of a third author (M.R.W) to
reach a consensus. We also scanned reference lists of rele-
vant articles (including reviews) for studies missed by the
original search. The “cited by” function in Web of Science
was used to check for citations of key studies.
Eligibility criteria
Studies were eligible for inclusion if they (i) were longitu-
dinal observational studies or RCTs that included patients
with infected elbow prostheses following TER and were
managed by a one- or two-stage revision strategy and (ii)
were followed up post-operatively for re-infection (which
was defined as recurrence of infection by the same organ-
ism(s) and/or re-infection with a new organism(s)) and/or
other clinical outcomes such as (a) function [as measured
by the Mayo elbow performance score (MEPS); flexion-
extension range of motion; and triceps function]; (b) pain;
(c) satisfaction; or (d) non-infection related complications
(such as implant failure, periprosthetic fracture, loosening,
haematoma, postoperative instability, nerve entrapment,
and triceps insufficiency).
Data extraction and quality assessment
One author (S.K.K.) initially extracted the data using a
data collection form which was standardised for this
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purpose. A second author (A.D.B) checked these data in-
dependently with the information in the original articles.
Any disagreements were discussed and a third author
(M.R.W) was involved to reach a consensus. We ex-
tracted the following pieces of information: Author and
year of publication, study design, study location, mean
or median age at baseline, proportion of male partici-
pants, type of revision surgery, revision surgery charac-
teristics, duration of follow-up after revision surgery,
number of re-infections after revision surgery, other clin-
ical outcomes, and adverse events. If information about the
same study was published twice or more often, we used
the most recent publication or the one with most up to
date information. The methodological quality of included
studies was assessed using the Methodological Index for
Non-Randomised Studies (MINORS), a well-established
validated instrument designed for assessing the quality of
non-randomised studies in surgery [20] and which has
been described in previous published papers [14, 15].
Briefly, this tool uses eight pre-defined factors which
include: a clearly reported aim, inclusion of consecutive pa-
tients, data collected in a prospective manner, endpoints
reflecting the aim of the study, study endpoints assessed in
an unbiased manner, follow-up duration which is appropri-
ate to the aim of the study, less than 5% loss to follow-up,
and prospective calculation of the study sample size. For
each of the domains, the tool assigns a score of 0 for “not
reported”, 1 for “reported but inadequate”, or 2 for “re-
ported and adequate”. These are then added into a total
score. A score of 16 is regarded as the global ideal score.
Data analysis
The re-infection rate, which was the primary outcome,
was computed from the number of re-infections within
the follow-up period following elbow revision surgery di-
vided by the total number of participants with PJI or num-
ber of elbow joints with PJI. Re-infection rates with 95%
confidence intervals (CIs) were estimated across the stud-
ies by employing the Freeman-Tukey variance stabilising
double arcsine transformation [21]. Details of the method
have been described previously [14, 15]. Given the limited
data, a pooled analysis was not performed. Non-infection
related adverse event rates (computed from the number of
adverse events or complications within follow-up period
following elbow revision surgery divided by the total num-
ber of participants with PJI or number of elbow joints with
PJI) with 95% CIs were also estimated across studies. Stata
MP 16 (Stata Corp, College Station, Texas, USA) was
employed for all statistical analyses.
Results
Study identification and selection
Of 97 records retrieved from the search, we excluded 83
articles based on titles and abstracts. On reviewing the
full texts of the remaining 14 articles, we excluded a fur-
ther 6 articles because (i) intervention was not relevant
(n = 5) or the article (ii) was a review paper (n = 1). This
left 8 articles eligible for inclusion in the review (Fig. 1;
Table 1) [12, 13, 22–27].
Study characteristics and study quality
Table 1 provides a summary of baseline characteristics
of one- and two-stage revision studies which were eli-
gible. Details on individual study baseline characteristics
and methodological quality are reported in Table 2. Of
the 8 eligible articles, 6 articles were based on two-stage
revision; 1 article evaluated the one-stage revision; and 1
article evaluated both one- and two-stage revision strat-
egies. Overall, there were 9 unique studies comprising
94 elbow joints revised for PJI (92 participants) and 13
re-infections. All included studies retrospectively ana-
lysed data based on observational cohort designs or case
series. The most common surgical indication for the
index TER was rheumatoid arthritis. We did not identify
any clinical trials comparing both revision strategies.
Studies were carried out in Europe (UK, Germany, and
Switzerland) and North America (United States of
America). Baseline study level surgery and clinical char-
acteristics could not be compared between the two revi-
sion strategies because of the limited number of studies
and outcome measures for one-stage revision. Studies
reported the diagnosis of PJI in a variety of ways, but
was mainly based on the presence of one or more of the
following criteria: (i) clinical, haematological and radio-
logical assessments suggesting the diagnosis with persist-
ent swelling and inflammation, high blood indices (such
as white cell count, C-reactive protein, or erythrocyte
sedimentation rate) and progressive radiolucent lines; (ii)
positive results of microbiological culture from preopera-
tive elbow joint aspirate, intraoperative periprosthetic tis-
sue, or sonication fluid of the removed plant; (iii) visible
purulence of a preoperative aspirate or intraoperative peri-
prosthetic tissue; (iv) wound findings such as the presence
of a sinus tract communicating with the prosthesis; and
(v) pathological findings on tissue sections. Staphylococcus
aureus (S. aureus) was reported as the most common
causative organism for elbow PJI in the majority of eligible
studies that provided these data (24 out of 71 elbow PJIs).
Intravenous flucloxacillin and rifampin were the most
common antibiotics administered following revision
surgery. The methodological quality scores of studies
included in the review ranged from 9 to 11.
Revision strategy and re-infection
Two studies were reported to have evaluated the one-stage
revision strategy and comprised of 7 elbow joints revised
for PJI (6 participants) and 1 re-infection (Tables 1 and 2).
The re-infection rate ranged from 0.0% (95% C: 0.0–79.3)
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to 16.7% (95%CI: 3.0–56.4) over a weighted mean follow-
up period of 6.4 years (Fig. 2).
Seven studies comprising of 87 elbow joints revised for
PJI (86 participants), reported 12 re-infections following
two-stage surgical revision (Tables 1 and 2). The re-
infection rate ranged from 0.0% (95% CI: 0.0–49.0) to
20.0% (95% CI: 3.6–62.4) over a weighted mean follow-
up period of 3.7 years (Fig. 2).
Other post-operative clinical outcomes
Of the six studies (1 one-stage and 5 two-stage studies)
that reported on mortality outcomes, none reported any
mortality event associated with the revision strategy
(Table 2). The same studies reported on non-infection
related adverse events following revision surgery and
these included explantation; revision; triceps weakness,
insufficiency, or rupture; ulnar fracture; ulnar nerve neu-
ropraxia; skin breakdown; humeral component loosen-
ing; and non-union (Table 2). The non-infection related
adverse event rate for one-stage which was based on one
study was 16.7% (95% CI: 3.0–56.4) and that for two-
stage revision ranged from 11.8% (95% CI: 4.7–26.6) to
20.0% (95% CI: 3.6–62.4) over a weighted mean follow-
up period of 3.7 years (Additional file 1: Figure S1).
Measures of function and pain between both revision
strategies could not be compared using statistical tests
because data from one-stage revision was based on lim-
ited data points (Table 3). However, median computed
values for range of motion, flexion, and MEPS seemed
to be better in the two-stage revision group compared
with the one-stage group; whereas extension was better
in one-stage revision. In 2 two-stage studies that re-
ported on measures of satisfaction, 4 out of 4 patients
reported satisfaction with the outcomes in one study
and in the other, 6 out of 7 patients were satisfied with
their outcomes. One one-stage study reported on this
outcome and indicated 4 out of 6 patients as being satis-
fied with the outcomes post-surgery.
Discussion
In this literature-based systematic review, the data sug-
gests that one-stage revision may be associated with
lower re-infection and non-infection related adverse
event rates compared with the two-stage strategy, al-
though the 95% confidence intervals overlapped and the
estimated rates were based on very limited data. Mea-
sures of function, pain, and satisfaction could not be
compared effectively because of limited data. However,
Fig. 1 PRISMA flow diagram
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the data suggested that range of motion, flexion, and
MEPS were improved in the two-stage revision group
compared with the one-stage group. These findings reflect
evidence observed in other joints showing that two-stage
revision may potentially be associated with improvement
in function, but lower rates of infection eradication com-
pared with one-stage revision [15, 16]. The findings can-
not be compared with previous work, given this is the first
ever systematic review to compare the clinical effective-
ness of one- and two-stage revision strategies for the man-
agement of infected elbow prosthesis.
Based on the limited data, it is difficult to make any
conclusions on which revision strategy is more clinically
effective. However, it appears the one-stage revision may
be potentially at least as effective compared with the
two-stage revision strategy, given the low re-infection
and adverse event rates. This review has also identified
large gaps in the existent literature – it appears that
though TERs are associated with higher incidence of PJIs
compared with hip or knee replacements [4–6], pub-
lished series on the use of the two most established PJI
treatment strategies are non-existent for elbows. It is ob-
vious that the paucity of data on treatment of elbow PJI
reflects the lower incidence of TER utilization [27] com-
pared to hip and knee replacements. This also raises the
question on whether infections in elbow arthroplasty
run a completely different course clinically and hence
can’t be treated with one- or two-stage revision surgery
in the same way as other joint replacements? As a result
of the thin soft tissue envelope of the elbow joint, it is
particularly susceptible to infection and this can be
worsened by inflammatory conditions (eg, arthritis),
Table 1 Summary characteristics of included studies
One-stage revision Two-stage revision
Eligible studies
Total number of studies included 2 7
Participants
Total number of participants 7 87
Total number of re-infections 1 11
Median (IQR) age (years) 64.9 (62.7–67.0) 64.7 (59.7–65.0)
Median (IQR) males (%) 0.0 (0.0–0.0) 31.0 (29.5–35.8)
Location
Europe 2 (7) 4 (59)
North America – 3 (28)
Asia – –
Study and surgery characteristics
Median (IQR) time from index surgery to infection diagnosis (months) 40.5 (40.5–40.5) 38.0 (24.0–51.9)
Median (IQR) duration of infection symptoms (days) – 60.4 (60.4–60.4)
Median (IQR) time from index surgery to revision surgery (months) – 57.1 (48.2–66.0)
Median (IQR) from infection diagnosis to revision surgery (months) – 15.0 (15.0–15.0)
Median (IQR) interval between stages (months) NA 6.1 (4.7–7.7)
Median (IQR) follow-up (years) 5.4 (4.0–6.8) 4.1 (3.0–4.3)
Median (IQR) duration of antibiotics (days) – 30.5 (11.3–49.7)
Median (IQR) duration of IV antibiotics (days) 37.2 (37.2–37.2) 8.8 (8.8–8.8)
Median (IQR) duration of oral antibiotics (days) – 2.5 (2.5–2.5)
Methodological quality (IQR) 10.5 (10.0–11.0) 10.0 (10.0–11.0)
Baseline clinical characteristics
Median (IQR) Range of motion (°) – 72.0 (50.0–94.0)
Median (IQR) Extension – 36.3 (36.3–36.3)
Median (IQR) Flexion – 101.3 (101.3–101.3)
Median (IQR) MEPS – 28.0 (22.9–52.5)
Median (IQR) Pain score – 15.0 (15.0–15.0)
IQR Interquartile range, IV Intravenous, MEPS Mayo elbow performance score, NA Not applicable; values are number of studies (number of participants) unless
stated otherwise
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medications used for treating these inflammatory dis-
eases and trauma [1]. Majority of elbow infections are
caused by skin bacteria such as S. aureus and S. epidermi-
dis. In contrast to PJIs of the hip and knee joints, pros-
thetic elbow infections rarely involve systemic symptoms
such as fever or malaise [4, 9]. Furthermore, unlike tests
for diagnosing prosthetic hip and knee infections, the
diagnostic utility of blood testing and joint aspiration for
PJI of the elbow is not well established [10]. In a review of
the diagnosis and management of prosthetic elbow infec-
tion, Somerson and colleagues note that given the lack of
objective criteria to diagnose PJI of the elbow, a high index
of clinical suspicion is required in addition to knowledge
of risk factors and discriminating interpretation of labora-
tory tests [10]. This especially makes the diagnosis and
treatment a challenge. We noted that the average interval
between stages in two-stage revision of infected elbow
joints was longer (6.1months) compared to other joints
(3–4months) [15, 16]; indeed, except for one study, the
majority of studies reported an average of more than 5
months duration between stages. This observation may re-
flect a more challenging and protracted course of treat-
ment for elbow PJI compared to that of other joints.
Although it is clear from the evidence that two-stage revi-
sion is currently the gold standard treatment for the man-
agement of elbow PJI; there are no clear management
guidelines or consensus as to which revision strategy is
the most effective because of the very limited data avail-
able. Other treatment options for infected elbow pros-
theses have been reported to be associated with acceptable
outcomes and these include DAIR and resection arthro-
plasty [7, 28]. However, debridement with suppressive
antibiotic therapy has been reported to offer benefit only
in the early post-operative period [9]. Resection arthro-
plasty is considered to be a salvage procedure which is
only of benefit for frail patients and those in whom elbow
function is not a major concern [7, 12]. The two-stage re-
vision strategy is commonly associated with high infection
control rates in lower limb replacement [14, 15] and
shoulder arthroplasty [16], but it requires two major surgi-
cal procedures which usually cause substantial functional
impairment and prolonged periods of hospitalisation [29].
It is also associated with high health service costs [8].
Data, generally from hip and knee joints, suggest that the
one-stage revision strategy may have several advantages
over the two-stage revision which include shorter periods
of hospitalisation and antibiotic therapy, better functional
results, and significant cost savings [30, 31]. Currently,
Fig. 2 Rates of re-infection in infected elbow prostheses treated by one- and two-stage revision. CI, confidence interval (bars)
Table 3 Post-operative clinical outcomes following one- and
two-stage revision strategies
One-stage revision Two-stage revision
Median (IQR) Range of
motion (°)
90.0 (80–90) 104.2 (97.0–111.4)
Median (IQR) Extension 35.0 (20.0–40.0) 18.8 (18.8–18.8)
Median (IQR) Flexion 120.0 (100.0–130.0) 129.6 (128.0–131.3)
Median (IQR) MEPS 67.6 (50.0–80.0) 83.4 (77.1–90.4)
Median (IQR) Pain score – 38.6 (38.6–38.6)
IQR Interquartile range, MEPS Mayo elbow performance score
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there is inadequate evidence to show that these ad-
vantages may be applicable to elbow joint PJI. Given
the significant burden of elbow PJI to the patient, the
surgeon and society as a whole, there is a great need
for further research in this area to address the exist-
ing gaps. We encourage investigators with access to
case series on elbow joint PJI treatment to publish
their outcomes on follow-up of their patients.
Given the sparse evidence on the topic, our review
represents the first attempt at bringing all the evi-
dence together using a systematic approach. The
search strategy was comprehensive and involved mul-
tiple databases, with manual reference scanning and
no language restrictions; which made it unlikely that
we had missed any relevant study conducted on the
topic. Though the data was limited and sparse on
outcome measures, harmonisation to consistent com-
parisons enabled interpretation of the findings. We
took into account the low event rates reported by the
majority of the studies. Finally, we conducted a de-
tailed assessment of the methodological quality of the
included studies based on a well validated tool. There
were important limitations to this review and these
were all related to the included studies. The included
studies recruited participants between 1978 to 2016;
hence given that some of these studies were con-
ducted several decades ago, inclusion of these data
may not reflect current standards of practice, as TER
implant designs have changed over time [32]. Pros-
thetic designs and surgical techniques have improved
as well as the introduction of newer and more effect-
ive antimicrobial therapies, therefore including these
older studies could have biased the outcomes. There
was a small possibility that two of the two-stage revi-
sion studies had overlapping patients [13, 24] and at-
tempts to get the original authors to confirm or
refute this proved futile. Whereas some studies did
not report the definition of PJI, those reported by
other studies varied and these could have biased the
findings; however, the majority of studies diagnosed
PJI using similar criteria. A robust comparison of all
outcomes of interest could not be made between the
two revision strategies because of the limited number
of published studies and outcome data reported. The
sample sizes were small and had very low event rates.
These limitations precluded detailed analyses and ef-
fective comparisons. The findings therefore need to
be interpreted with caution. However, the current
findings are timely and relevant because they provide
substantial insight on the huge gaps in the existing
literature. In the absence of case series to compare
the effectiveness of the two revision strategies, there
is a potential that data from national joint registries
may be useful in answering these questions.
Conclusions
No strong conclusions can be drawn because of limited
data. The one-stage revision strategy may be potentially
as clinically effective as the two-stage revision for the
treatment of elbow PJI, but further data is required.
Remarkable findings are the clear gaps in the existing
literature and studies are urgently warranted to evaluate
the clinical effectiveness of one- and two-stage revision
strategies for treating elbow PJI.
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